Kun for helsepersonell

Søk

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss

Menu

Close

Om ZaviceftaVirkningsmekanismePatogen dekningTidlig hensiktsmessig behandlingIDSA anbefalingØkonomiske holdepunkterSpørsmål og svar om ZAVICEFTAPasientprofilerHAP/VAP pasientcUTI pasientcIAI pasientPediatriske pasienterSpørsmål og svar - FAQsEffekt Real-world evidenceEffektdataSpørsmål og svar om effektSikkerhetSikkerhet hos voksneSikkerhet hos barn/ungdomSpørsmål og svar om sikkerhetDoseringDosering hos voksneDosering hos barn/ungdomSpørsmål og svar om dosering
Pediatriske pasienterAntimicrobial resistance is a growing threat, with treatment options urgently needed for patients at risk
of MDR Gram-negative infections1,2

Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes.2

ZAVICEFTA: Paediatric patient profiles

cUTI patient

cIAI patient

Tab Number 3

Tab Number 4

Tab Number 5

cUTI patient profile*

Identifying patients with cUTI at high risk of MDR Gram-negative infections.

Paediatric patient profile - cUTI

 Emily 1-year-old girl

Medical history

  • Spina bifida
  • Neurogenic bladder
  • Recurrent UTIs
  • Requires intermittent use of catheter
  • Previous ESBL in urine
 Clinical presentationEmily, for a second time, has been admitted to the hospital through a paediatric urology clinic due to clinical deterioration. Observations
Raised temperature
Raised inflammatory markers

Diagnosis

Suspected cUTI

Suspected pathogens

K. pneumoniae, including those resistant to carbapenems (KPC)

Treatment considerations

Infections due to MDR Gram-negative pathogens, including ESBL-producing bacteria, are increasing in children and have been associated with higher mortality3,8,9

Risk factors that contribute to a higher mortality rate include3,10

Why ZAVICEFTA is an appropriate choice for your cUTI paediatric patients

cIAI patient profile*

Identifying paediatric patients with cIAI at high-risk of MDR Gram-negative infections.

Paediatric patient profile - cIAI

 Matthew
 5-year-old boy

Medical history

  • Global developmental delay
  • Gut dysfunction
  • Total parenteral nutrition fed
  • Under the care of a paediatric gastrointestinal team
  • Various previous surgical procedures
  • 3 months ago: CPE rectal screen positive for Klebsiella oxytoca (KPC)
 Clinical presentation
  • Matthew was admitted to hospital for a bowel resection 
  • 3 days post-operation, Matthew experienced clinical deterioration
 Observations
Raised temperature
Raised inflammatory markers
Diarrhoea, nausea and vomiting
Severe breathlessness

Diagnosis

Suspected cIAI

Suspected pathogens

MDR Gram-negative pathogens, including K. pneumoniae, possibly carbapenem- and colistin-resistant

Treatment considerations

  • CPE, including KPC-producing strains, are the culprits for the rapid global spread of CRE8 and are associated with higher mortality8,9
  • Severe sepsis and septic shock due to these infections represent a significant cause of morbidity and mortality in these paediatric patients11

Risk factors that contribute to a higher mortality rate include3,10

Why ZAVICEFTA is an appropriate choice for your cUTI paediatric patients

Safe and effective treatment options are urgently needed to address the
growing threat of MDR Gram-negative infections in paediatric patients.15-17

Learn more about paediatric dosing
in ZAVICEFTA

Watch the video for a step-by-step guide in paediatric dosing in ZAVIECFTA for cUTI and cIAI paediatric patients.

Explore moreInfectious Thinking

Listen to episode 4 of our ‘Infectious Thinking’ podcast on high-risk paediatric patients with cIAI.

LoadingPrescribing information

View ZAVICEFTA prescribing information.

Loading

Footnotes:

The example described here is not an actual patient, but rather a fictitious representation of a scenario for which ZAVICEFTA (ceftazidime–avibactam) could be considered.Avibactam does not inhibit class B enzymes (metallo-β-lactamases) and does not inhibit many class D enzymes.11To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.11The total treatment duration shown may include IV ZAVICEFTA followed by appropriate oral therapy.11Consideration should be given to official guidance on the appropriate use of antibacterial agents.11To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.1

Abbreviations:

COPD, chronic obstructive pulmonary disease; CRE, carbapenem-resistant Enterobacterales; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; ESBL, extended spectrum beta-lactamase; HAP, hospital-acquired pneumonia; ICU, intensive care unit; KPC, Klebsiella pneumoniae carbapenemase; MDR, multidrug-resistant; OXA, oxacillinase; UTI, urinary tract infection VAP, ventilator-associated pneumonia. 

References:

Timsit J-F, et al. Intensive Care Med 2019; 45:573–91.Bonine NG, et al. Am J Med Sci 2019;357:102–10.Bassetti M, et al. Infect Drug Resist 2020;13:1763–73.Miller BM, et al. Am J Infect Control 2016;44:134–7.De Waele J, et al. Intensive Care Med 2018;44:189–96.Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23.Harris AD, et al. Emerg Infect Dis 2007;13:1144–9.Meropol SB, et al. J Pediatric Infect Dis Soc 2018;7:36–45.Aguilera-Alonso D, et al. Antimicrob Agents Chemother 2020;64:e02183-19.Folgori L, Bielicki. J Pediatr Intensive Care 2019;8:17–24.ZAVICEFTA. Summary of Product Characteristics, 2022.Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–71.Zhanel GG, et al. Drugs 2013;73:159–77.Mazuski JE, et al. Surg Infect 2017;18:1–76.Bradley JS, et al. Pediatr Infect Dis J 2019;38:920–8.Bradley JS, et al. Pediatr Infect Dis J 2019;38:816–24.Sader HS, et al. Pediatr Infect Dis J 2018;37:549–54.Pasientprofiler
Preparatomtale
PP-ZVA-NOR-0141 Mai 2023

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei